Compassion Not Greed, Right to Try – Basic Human Rights: Reversals of Disease & Disabilities (1of2)

Founder & CEO of Ambrose Cell Therapy, Matthew Feshbach, returns to the show to discuss how his company is making amazing progress towards helping those who have been left behind by traditional medicine and how the new Right to Try laws have changed the landscape for many. He explains how human fat stores powerful human stem cells which can be used to rebuild tissue, muscle, reduce inflammation and much more. He shares success stories and amazing possibilities for the future. You can see more at https://AmbroseCellTherapy.com   99.99% Pure C60 Gel Capsules in Blackseed Oil - Build up Your Immunities & Protect Yourself! See more details, including videos and a personalized letter from Jeff, about his extraordinary journey discussed in the show - see here   Support independent journalism by joining Patreon. Receive special discounts and exclusive content, sign up @ https://Patreon.com/SarahWestall    Stay informed on the latest shows by signing up for my weekly newsletter @ http://SarahWestall.com   Follow me on Twitter @ https://twitter.com/westall_sarahw   MUSIC CREDITS: "Apex" by Aakash Gandhi for broad internet media use, including video and audio     Jump start your new years resolution goals with C60 gel caps, Tetrogen Fat burning, Telomere lengthening and more! Be sure to get the latest coupons at the store below Get the latest discount codes on the very best products at the Independent Journalist Shop:    Matthew Feshbach Biography Matthew Feshbach began his entrepreneurial career directly out of high school. After working for more than 30 years as an investor, he co-founded a clinic to provide stem cell procedures to those with congestive heart failure who have exhausted available treatment options from the current standard of care. Jumping from investments to healthcare might seem like quite a tremendous shift of gears, but this transition—the reason for which may not be immediately obvious—will make sense to those friends and associates who know him well. In 1982, along with his brothers Kurt and Joe, Matthew Feshbach founded the first short-only hedge fund, Feshbach Brothers. Starting out, Matt leaned on the only formal training he had—a mail-order course on securities analysis from the New York Institute of Finance. Intuitively, he knew that to succeed as an investor with limited background and training that he would have to work differently than those competing for investment ideas. Thus was born the idea of going short instead of long, and not relying on Wall Street analysts but rather doing intensely deep “scuttlebutt” research—a term coined  by Matt’s investment hero, the late Philip Fisher. And, most importantly, maintaining the courage of his convictions. Matt learned a great deal in 30 years about the highs and lows of investing, and along with his brothers built a billion dollar hedge fund. He also learned to spot executive team members who had the “right stuff” in communication, leadership and management styles, and he became a keen student of what it took to successfully run a company. Though the market changed and short-only was no longer a viable strategy in the 1990s, his time spent analyzing enabled him to be able to boil down all the complexities and fluff in business to the simple facts—the ones that mattered. Matt’s interest in the potential of stem cell procedures began in 2009 when a fellow investor introduced him to a public company in the field. After recognizing the regenerative and restorative potential of stem cells, a deeper look into clinical research showed that the most abundant source of stem cells comes from one’s own body fat (medically known as adipose tissue.) Adipose-derived stem and regenerative cells (or ADRCs) have been seen in clinical trials to initiate new blood vessel growth in tissue that lacks blood flow, or “ischemic tissue” as doctors refer to it. He connected with top cardiologists in the belief that this science could be applie... See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.